Why the study?
Does sirtuin activation mitigate doxorubicin-induced cardiotoxicity without reducing antineoplastic activity?
Population
Patients receiving anthracycline chemotherapy and preclinical models of doxorubicin-induced cardiotoxicity
Design
Review
Authors
Loading...
Sirtuin activation may protect cardiac mitochondria during doxorubicin therapy; hypothesis-generating for clinical trials.
Does sirtuin activation mitigate doxorubicin-induced cardiotoxicity without reducing antineoplastic activity?
Sirtuin activation represents a potential therapeutic strategy to mitigate doxorubicin-induced cardiotoxicity by preserving mitochondrial function.
Vernon W. Dolinsky (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: